CLIDEX
LIVE

Serial Number

79391496

Owner

Dx & Vx Co., Ltd.

Attorney

James R Menker

Filing Date

Nov 9, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CLIDEX Trademark

Serial Number: 79391496 • Registration: 7971334

CLIDEX is a trademark filed by Dx & Vx Co., Ltd. on November 9, 2023. The trademark is classified under Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Dx & Vx Co., Ltd.

1003-ho, 173, Digital-ro,

Entity Type: 03

Trademark Details

Filing Date

November 9, 2023

Registration Date

October 7, 2025

Published for Opposition

August 19, 2025

Goods & Services

Medical co-diagnostic services; medical diagnostic services; medical co-diagnostic services for medical purposes; medical testing in the field of molecules for diagnostic purposes; medical and health services relating to DNA, genetics and genetic testing; genetic testing for medical purposes; provision information about genetic testing for medical treatment purposes; provision of medical information; medical analysis services relating to, blood testing, genetic testing, microbiological analysis, urine analysis, diagnostic imaging interpretation, molecular diagnostics, pathology services, hormone level testing, drug screening, and disease biomarkers analysis; telemedicine services; medical analysis services relating to the treatment of persons; medical services; medical analysis of human tissues for the purpose of medical treatment of persons; medical examination services; provision of medical services; health clinic services for medical purposes; medical analysis relating to clinical data for medical diagnosis and treatment purposes; providing health care information via electronic means; medical analysis for the diagnosis and treatment of persons; medical information services relating to medical products; medical diagnostic, testing and analysis services for medical diagnostic and treatment purposes; health advice being health and information services; medical and pharmaceutical consultation

In vitro diagnostic devices, namely, medical imaging apparatus, medical diagnostic apparatus for analyzing and measuring electrolytes in the body; in vitro diagnostic devices for medical purposes, namely, medical test kits for diabetes monitoring for home use, devices for monitoring blood glucose for medical purposes, genetic testing apparatus for medical purposes; medical apparatus and instruments, namely, surgical apparatus and instruments for medical use, oxygen monitors for medical use, medical imaging apparatus, medical drapes, medical endoscopes, anesthesia machines, blood pressure measuring apparatus, defibrillators; apparatus for clinical diagnosis, namely, medical imaging apparatus, ultrasound probes for medical use, electrocardiographic (ECG) recorders, hematology analyzers for medical diagnostic uses, clinical thermometers; DNA extraction and purification apparatus for DNA testing for medical purposes; apparatus for use in medical analysis, namely, apparatus for blood analysis, flow cytometers for medical diagnostic uses; genetic testing apparatus in the nature of apparatus for DNA and RNA testing for medical purposes; diagnostic apparatus for medical purposes, namely, medical imaging apparatus, ultrasound probes for medical use, MRI apparatus for medical purposes, X-ray CT scanners; measuring instruments for medical purposes, namely, devices for measuring wounds, heartbeat measuring apparatus, pulse oximeters for medical purposes, blood glucose meters; medical genetic analyzer being apparatus for DNA and RNA testing for medical purposes; biometric measuring devices for medical purpose, namely, fetal heartbeat monitors, wearable wrist monitors used to measure biometric data for medical use; medicine testing apparatus, namely, biological pharmaceutical blood analysis apparatus, untreated multi-drug testing dip cards for drug use testing purposes, immunochemical testing apparatus for medical use, eye testing apparatus; cell testing apparatus for medical purposes being apparatus for DNA and RNA testing for medical purposes; telemetry apparatus for medical purposes; orthopedic devices for diagnostic and therapeutic use; medical fluid injectors for medical purposes; apparatus for analyzing substances for medical use, namely, breath gas analyzers for medical diagnostics, apparatus used in implementing diagnosis tests designed to detect the abnormal prion protein; apparatus for the regeneration of stem cells for medical purposes; X-ray apparatus for medical purposes; apparatus for analyzing blood for medical use; syringes for injection of medical substances; medical products, namely, miniaturized biofeedback sensors for use in gene analysis and diagnosis; receptacles for applying medicines, namely, hypodermic syringes, spacers for inhalers, transdermal drug delivery patches sold without medication, and eye drop guides

Scientific research in the field of biomedicine; medical research; DNA analysis for scientific research purposes; providing scientific research information relating to scientific analysis of genetic information via online networks; medical and scientific research, namely, conducting clinical trials for others; scientific research in the field of gene analysis; remote monitoring of medical diagnostic devices to ensure proper functioning; product research and development in the field of medical products; medical research laboratories; consultancy in analysis of genomics for medical research purposes; stem cell research services; biological analysis, namely, genetic testing for scientific research purposes in the field of medicine; biological research, namely, genetic testing for scientific research purposes; product development in the field of devices for biological chemicals analysis; providing information in the fields of medical research; product development of medical devices; medical research laboratory services for predicting disease; scientific research in the field of protein analysis; scientific research in the field of multiple nucleotide sequence analysis; research and development of medical apparatus and instruments for others; scientific research in the field of processing and handling of chemical reagents; medical research services relating to clinical data

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 7, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 7, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 7, 2025 R.PR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 3, 2025 NRCC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 5, 2025 OPNX
LIMITATION OF GOODS RECEIVED FROM IB
Aug 29, 2025 LIMG
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 19, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 19, 2025 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 13, 2025 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 13, 2025 NONP
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 13, 2025 OPNR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 9, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 9, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 9, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 9, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 9, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 29, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 29, 2025 CRFA
ASSIGNED TO LIE
May 29, 2025 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 18, 2025 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 8, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 8, 2025 GNSL
SUSPENSION LETTER WRITTEN
Jan 8, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 7, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 7, 2025 TROA
REFUSAL PROCESSED BY IB
Jul 28, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 11, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 11, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 21, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jun 20, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 17, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 24, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 24, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 14, 2024 REPR